Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN5069 in Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Intravenously or Subcutaneously Administered REGN5069 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2018

At a glance

  • Drugs REGN-5069 (Primary) ; REGN-5069 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 15 Oct 2018 Planned End Date changed from 8 May 2019 to 10 May 2019.
    • 15 Oct 2018 Planned primary completion date changed from 8 May 2019 to 10 May 2019.
    • 05 Sep 2018 Planned End Date changed from 12 Apr 2019 to 8 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top